In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
no speaker photo
Speaker
Nikolaus Marx
Nikolaus Marx Nikolaus Marx

RWTH University Hospital Aachen, Aachen (Germany)

Specialities : Risk Factors and Prevention , Basic Science, Chronic Heart Failure, Coronary Artery Disease Chronic

32 presentations from this speaker

Analysis of first plus recurrent cardiovascular (CV) and hospitalisation events in the CAROLINA trial

Event : ESC Congress 2020

  • Session : Improving Cardiovascular Function and Clinical Outcome in Diabetes Using New Guideline-Based Pharmacotherapy
  • Speaker : N Marx (Aachen,DE)

The cardiology challenge to manage diabetes in cardiovascular risk reduction.

Event : ESC Congress 2020

  • Session : Expanding focus for cardiologists: The diabetic patient and cardiovascular outcomes
  • Speaker : N Marx (Aachen,DE)
  • Organised by PACE-CME, supported by Novo Nordisk A/S in the form of an educational grant

Are the new ‘diabetes’ medicine really cardiology drugs?

Event : ESC Congress 2019

  • Session : Impact of novel guidelines: transforming diabetes management in cardiology
  • Speaker : J Deanfield (,GB), N Marx (Aachen,DE)
  • Organised by PACE-CME, supported with an educational grant provided by Novo Nordisk

Challenge the experts: panel and audience discussion

Event : ESC Congress 2019

  • Session : Impact of novel guidelines: transforming diabetes management in cardiology
  • Speaker : F Krag Knop (Copenhagen,DK), J Deanfield (,GB), F Cosentino (Stockholm,SE), N Marx (Aachen,DE)
  • Organised by PACE-CME, supported with an educational grant provided by Novo Nordisk

Evidence, guidelines, clinical practice – The evolving role of cardiologists in the SGLT2 inhibitor era

Event : ESC Congress 2019

  • Session : Evidence, guidelines, clinical practice – The evolving role of cardiologists in the SGLT2 inhibitor era
  • Speaker : N Marx (Aachen,DE), S Anker (Berlin,DE)
  • Sponsored by The Boehringer Ingelheim and Eli Lilly and Company Alliance

New evidence from cardiovascular outcome trials.

Event : ESC Congress 2019

  • Session : 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the European Association for the Study of Diabetes (EASD)
  • Speaker : N Marx (Aachen,DE)

Taking the initiative: the cardiologist´s perspective

Event : ESC Congress 2019

  • Session : SGLT2 inhibitors in clinical cardiology: modern-day cardiovascular management in patients with type 2 diabetes
  • Speaker : N Marx (Aachen,DE)
  • Sponsored by The Boehringer Ingelheim, Eli Lilly and Company Alliance

The cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

Event : ESC Congress 2019

  • Session : Expanding opportunities for SGLT2i in clinical cardiology
  • Speaker : N Marx (Aachen,DE)
  • Organised by PACE-CME, supported with an educational grant provided by Boehringer-Ingelheim/Lilly

Welcome and introduction

Event : ESC Congress 2019

  • Session : Evidence, guidelines, clinical practice – The evolving role of cardiologists in the SGLT2 inhibitor era
  • Speaker : N Marx (Aachen,DE), S Anker (Berlin,DE)
  • Sponsored by The Boehringer Ingelheim and Eli Lilly and Company Alliance

Advancing the standard of care in patients with type 2 diabetes and established cardiovascular disease: how can we improve patient outcomes? .

Event : ESC Congress 2018

  • Session : Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice
  • Speaker : N Marx (Aachen,DE), D McGuire (Dallas,US), JA Udell (Toronto,CA), S Verma (Toronto,CA), N Sattar (Glasgow,GB)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Cardiometabolic syndrome: how diabetes AGE the arteries.

Event : ESC Congress 2018

  • Session : Cardiovascular prevention in diabetes
  • Speaker : N Marx (Aachen,DE)
  • European Association of Preventive Cardiology (EAPC)

Diabetes treatment in ischemic heart disease – Key messages.

Event : ESC Congress 2018

  • Session : Key messages from the most popular ESC webinars
  • Speaker : N Marx (Aachen,DE), PJ Grant (Leeds,GB)
  • ESC Education committee

Panel discussion: discussing the benefits in cardiovascular risk, diabetes & heart failure.

Event : ESC Congress 2018

  • Session : Targeting SGLT2 in clinical cardiology: discussing the benefits in cardiovascular risk, diabetes & heart failure
  • Speaker : S Jacob (Villingen,DE), J Deanfield (,GB), N Marx (Aachen,DE), F Cosentino (Stockholm,SE)
  • Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Boehringer Ingelheim/Lilly

SGLT2 inhibition in cardiology: what is the profile of benefit? .

Event : ESC Congress 2018

  • Session : Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure (EBAC Accredited)
  • Speaker : N Marx (Aachen,DE)
  • Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Boehringer Ingelheim/Lilly

Summary and close - Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice.

Event : ESC Congress 2018

  • Session : Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice
  • Speaker : N Marx (Aachen,DE)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Targeting SGLT2 inhibition in cardiology: what is the profile of benefit?

Event : ESC Congress 2018

  • Session : Targeting SGLT2 in clinical cardiology: discussing the benefits in cardiovascular risk, diabetes & heart failure
  • Speaker : N Marx (Aachen,DE)
  • Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Boehringer Ingelheim/Lilly

Welcome and introduction - Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice.

Event : ESC Congress 2018

  • Session : Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice
  • Speaker : N Marx (Aachen,DE)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Chair’s summary and audience Q&A.

Event : ESC Congress 2017

  • Session : Improving cardiovascular outcomes in patients with type 2 diabetes: where does the evidence lead us?
  • Speaker : N Marx (Aachen,DE)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Close – Improving cardiovascular outcomes in patients with type 2 diabetes: where does the evidence lead us?

Event : ESC Congress 2017

  • Session : Improving cardiovascular outcomes in patients with type 2 diabetes: where does the evidence lead us?
  • Speaker : N Marx (Aachen,DE)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Empaglifozin (SGLT-2 inhibition).

Event : Heart Failure 2017

  • Session : Novel drugs: how do they work?
  • Speaker : N Marx (Aachen,DE)

Experience with empagliflozin: insights from practice.

Event : ESC Congress 2017

  • Session : Improving cardiovascular outcomes in patients with type 2 diabetes: where does the evidence lead us?
  • Speaker : N Marx (Aachen,DE), D McGuire (Dallas,US), F Zannad (Vandoeuvre,FR), JA Udell (Toronto,CA)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Introduction – Improving cardiovascular outcomes in patients with type 2 diabetes: where does the evidence lead us?

Event : ESC Congress 2017

  • Session : Improving cardiovascular outcomes in patients with type 2 diabetes: where does the evidence lead us?
  • Speaker : N Marx (Aachen,DE)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Coprevalence of comorbidities and their role in the choices of treatment for the diabetic patient with cardiovascular disease.

Event : ESC Congress 2016

  • Session : Clinical considerations for cardiologists: exploring the evidence for primary and secondary prevention in type 2 diabetes
  • Speaker : N Marx (Aachen,DE)
  • Sponsored by MSD

Q&A - Clinical considerations for cardiologists: exploring the evidence for primary and secondary prevention in type 2 diabetes.

Event : ESC Congress 2016

  • Session : Clinical considerations for cardiologists: exploring the evidence for primary and secondary prevention in type 2 diabetes
  • Speaker : N Marx (Aachen,DE), PW Armstrong (Alberta,CA), L Leiter (Toronto,CA), L Ryden (Stockholm,SE)
  • Sponsored by MSD

Closing remarks - Lessons learned from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Cardiovascular (CV) safety trial and the evolving role of sitagliptin in the treatment of patients with type 2 diabetes and cardiovascular disease

Event : ESC Congress 2015

  • Session : Lessons learned from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Cardiovascular (CV) safety trial and the evolving role of sitagliptin in the treatment of patients with type 2 diabetes and cardiovascular disease
  • Speaker : N Marx (Aachen,DE)
  • Sponsored by MSD

Welcome and introductions - Lessons learned from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Cardiovascular (CV) safety trial and the evolving role of sitagliptin in the treatment of patients with type 2 diabetes and cardiovascul

Event : ESC Congress 2015

  • Session : Lessons learned from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Cardiovascular (CV) safety trial and the evolving role of sitagliptin in the treatment of patients with type 2 diabetes and cardiovascular disease
  • Speaker : N Marx (Aachen,DE)
  • Sponsored by MSD

Cardio-diabetology or diabeto-cardiology: conclusion and take home message.

Event : ESC Congress 2014

  • Session : Cardio-diabetology or diabeto-cardiology
  • Speaker : N Marx (Aachen,DE)

Cardiovascular effects of DPP-4 inhibitors - What do we know so far?

Event : ESC Congress 2013

  • Session : Macrovascular risk in patients with type 2 diabetes mellitus: where do dipeptidyl peptidase-4 inhibitors fit?
  • Speaker : N Marx (Aachen,DE)
  • Sponsored by MSD

Diabetic challenge for the interventional cardiologist.

Event : ESC Congress 2013

  • Session : Cardiodiabetology: do we need a new specialty?
  • Speaker : N Marx (Aachen,DE)

Management of cardiovascular disease in diabetes.

Event : ESC Congress 2013

  • Session : ESC Guidelines on diabetes, pre-diabetes and cardiovascular disease
  • Speaker : N Marx (Aachen,DE)

Panel discussion and closing remarks: macrovascular risk in patients with type 2 diabetes mellitus.

Event : ESC Congress 2013

  • Session : Macrovascular risk in patients with type 2 diabetes mellitus: where do dipeptidyl peptidase-4 inhibitors fit?
  • Speaker : N Marx (Aachen,DE), J Kastelein (Amsterdam,NL), S Del Prato (Pisa,IT), R Chilton (San Antonio,US)
  • Sponsored by MSD

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are